China-based Peijia Medical Limited has signed a memorandum of strategic cooperation with China Resources Pharmaceutical Commercial Group Medical Devices Co. Ltd, it was reported on Friday.
Both firms are to collaborate on the commercialisation of transcatheter aortic valve replacement products, with the intention of providing more Chinese medical staff and patients with better quality goods. The collaboration integrates Peijia Medical's products with China Resources Pharmaceutical Commercial's marketing channels.
Peijia Medical's TaurusOne transcatheter aortic valve replacement was approved for commercial use in April this year.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project